Harnessing gemcitabine metabolism: A step towards personalized medicine for pancreatic cancer

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 6, 2012, Pages 341-346

  Saif, Muhammad Wasif ^a   Lee, Yoomi ^b   Kim, Richard ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

gemcitabine; metabolism; pancreatic cancer; pharmacogenomics

Indexed keywords

CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ANOREXIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TRANSPORT; FATIGUE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PANCREAS CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 84871853036     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012453755     Document Type: Article

References (23)

1. Bergman A. Adema A. Balzarini J. Bruheim S. Fichtner I. Noordhuis P. et al. (2011) Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 29: 456–466.
2. Burris H. Moore M. Andersen J. Green M. Rothenberg M. Modiano M. et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413.
3. Conroy T. Desseigne F. Ychou M. Bouché O. Guimbaud R. Bécouarn Y. et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–1825.
4. Cunningham D. Chau I. Stocken D. Valle J. Smith D. Steward W. et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513–5518.
5. Farrell J. Elsaleh H. Garcia M. Lai R. Ammar A. Regine W. et al. (2008) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136: 187–195.
6. Giovanetti E. Del Tacca M. Mey V. Funel N. Nannizzi S. Ricci S. et al. (2006) Transcription analysis of human equilibrative transporter 1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928–3935.
7. Grunewald R. Abbruzzese J. Tarassoff P. Plunkett W. (1991) Saturation of 2′,2′- difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27: 258–262.
8. Jemal A. Siegel R. Xu J. Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
9. Kim R. Tan A. Lai K. Jiang J. Wang Y. Rybicki L. et al. (2011) Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M 1 (RRM1) in resected pancreatic cancer. Cancer 117: 3126–3134.
10. Kim S. Lim D. Jang K. Lim T. Lee J. Choi Y. et al. (2011) Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 10: 1993–1999.
11. Mackey J. Mani R. Selner M. Mowles D. Young J. Belt J. et al. (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349–4357.
12. Marechal R. Bachet J. Mackey J. Demetter P. Graham K. Couvelard A. et al. (2011) Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT 1 and dCK protein expression. J Clin Oncol 29(15 Suppl.): abstract 4024.
13. McGuigan C. Habib N. Wasan H. Gabra H. Jiao L. Slusarczyk M. et al. (2011) A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine. J Clin Oncol 29(15 Suppl.): abstract 13540.
14. Moore M. Goldstein D. Hamm J. Figer A. Hecht J. Gallinger S. et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966.
15. Mori R. Ishikawa T. Ichikawa Y. Taniguchi K. Matsuyama R. Ueda M. et al. (2007) Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17: 1201–1205.
16. Nilsson B. Hendlisz A. Castella M. Aamdal S. Dueland S. Nyakas M. et al. (2009) First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors. J Clin Oncol 27(15 Suppl.): abstract 2577.
17. Poplin E. Feng Y. Berlin J. Rothenberg M. Hochster H. Mitchell E. et al. (2009) Phase III randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed dose rate infusion) compared with gemcitabine (30 minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778–3785.
18. Saif M. (2011) Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series. Anticancer Res 31: 1039–1042.
19. Spratlin J. (2011) Biomarker directed adjuvant chemotherapy for resected pancreas cancer. Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/record/NCT01411072 (accessed 19 June 2012).
20. Spratlin J. Sangha R. Glubrecht D. Dabbagh L. Young J. Dumontet C. et al. (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956–6961.
21. Tempero M. Plunkett W. Ruiz van Haperen V. Hainsworth J. Hochster H. Lenzi R. et al. (2003) Randomized phase II comparison of dose intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402–3408.
22. Touroutoglou N. Gravel D. Raber M. Plunkett W. Abbruzzese J. (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9: 1003–1008.
23. von Hoff D. Ramanathan R. Borad M. Laheru D. Smith L. Wood T. et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I / II trial. J Clin Oncol 29: 4548–4554.